DUPILUMAB (Dupixent®)

Clinical Indication

Type 2 inflammation in asthma inadequately controlled by high dose ICS

Comments

As part of FOC scheme

Date of classification

October 2020

Review date

October 2020

Red

Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).